Table 25.
In vitro inhibition of cancer cell lines growth in leukaemia, CNS, ovarian and breast cancer subpanels by compounds 21a, 22a–d.
| Cell Line | GI50 (µM) a | ||||
|---|---|---|---|---|---|
| 21a | 22a | 22b | 22c | 22d | |
| Leukaemia | |||||
| CCRF-CEM | ND b | ND | 1.51 | 1.52 | 1.13 |
| RPMI82226 | 2.74 | 0.37 | 1.91 | 3.90 | 2.80 |
| SR | 3.24 | 0.22 | 4.24 | 11.3 | 9.53 |
| CNS Cancer | |||||
| SF-295 | 2.33 | 0.50 | 2.93 | 3.29 | 3.14 |
| SF-539 | 4.21 | 0.16 | 4.37 | 11.7 | 7.14 |
| SNB-19 | 1.15 | 0.56 | 4.81 | 7.88 | 5.26 |
| U251 | 3.37 | 0.36 | 3.86 | 6.46 | 4.19 |
| Ovarian Cancer | |||||
| IGROV1 | 3.24 | 0.25 | <0.01 | 1.14 | 1.86 |
| OVCAR-5 | 4.68 | 0.38 | >100 | 5.50 | 8.13 |
| Breast Cancer | |||||
| MCF-7 | 2.30 | 0.39 | 2.74 | 3.05 | 3.55 |
| MDA-MB-435 | 3.31 | 0.22 | 4.52 | 5.87 | 5.76 |
a Concentration (µM) that inhibits 50% net cell growth. b ND = Not Determined.